A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

被引:5
|
作者
Metairie, Marie [1 ]
Benoit, Louise [1 ,2 ]
Koual, Meriem [1 ,2 ]
Bentivegna, Enrica [1 ]
Wohrer, Henri [1 ]
Bolze, Pierre-Adrien [3 ]
Kerbage, Yohan [4 ]
Raimond, Emilie [5 ]
Akladios, Cherif [6 ]
Carcopino, Xavier [7 ]
Canlorbe, Geoffroy [8 ,9 ,10 ]
Uzan, Jennifer [11 ]
Lavoue, Vincent [12 ]
Mimoun, Camille [13 ]
Huchon, Cyrille [13 ,16 ]
Koskas, Martin [14 ]
Costaz, Helene [15 ]
Margueritte, Francois [16 ]
Dabi, Yohann [17 ]
Touboul, Cyril [17 ]
Bendifallah, Sofiane [17 ]
Ouldamer, Lobna [15 ,18 ]
Delanoy, Nicolas [19 ]
Nguyen-Xuan, Huyen-Thu [1 ]
Bats, Anne-Sophie [1 ,20 ,21 ]
Azais, Henri [1 ,20 ,21 ]
机构
[1] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris AP HP, Dept Gynaecol Oncol & Breast Surg, F-75015 Paris, France
[2] Univ Paris Cite, Ctr Univ St Peres, INSERM UMR S 1124, F-75006 Paris, France
[3] Univ Lyon 1, Lyon Sud Univ Hosp, Dept Gynaecol & Oncol Surg & Obstet, Hosp Civils Lyon, F-69002 Lyon, France
[4] Univ Lille, Dept Gynaecol Surg, CHU Lille, F-59000 Lille, France
[5] Inst Alix Champagne Univ Hosp, Dept Obstet & Gynaecol, F-51100 Reims, France
[6] Hop Univ Strasbourg, Dept Gynaecol, F-67200 Strasbourg, France
[7] Aix Marseille Univ AMU, Univ Avignon, Hop Nord, Dept Obstet & Gynaecol, F-13397 Marseille, France
[8] Pitie Salpetriere, Assistance Publ Hop Paris AP HP, Dept Gynaecol & Breast Surg & Oncol, F-75013 Paris, France
[9] Sorbonne Univ, Ctr Rech St Antoine CRSA, Canc Biol & Therapeut, INSERM UMR S 938, F-75012 Paris, France
[10] Sorbonne Univ, Univ Inst Canc, F-75013 Paris, France
[11] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Obstet Gynecol & Reprod Med, F-94000 Creteil, France
[12] Univ Rennes 1, Hop Sud, Dept Gynaecol Surg, equipe 8, F-35000 Rennes, France
[13] Univ Paris, Hop Lariboisiere, Dept Gynaecol Oncol & Breast Surg, F-75010 Paris, France
[14] Hop Xavier Bichat, Assistance Publ Hop Paris AP HP, Div Gynaecol Oncol, F-75018 Paris, France
[15] Georges Francois Leclerc Ctr, Dept Surg Oncol, F-21000 Dijon, France
[16] Ctr Hosp Intercommunal Poissy St Germain en laye, Dept Gynaecol, Site Hosp Poissy, F-78498 Poissy, France
[17] Hop Tenon, AP HP Assistance Publ Hop Paris, Dept Gynaecol ans Obstet, F-75020 Paris, France
[18] Hop Univ Tours, Dept Gynaecol, F-37000 Tours, France
[19] Hop Europeen Georges Pompidou, AP HP Assistance Publ Hop Paris, Dept Med Oncol, F-75015 Paris, France
[20] Univ Paris Cite, Ctr Rech Cordeliers, INSERM UMR S 1147, F-75006 Paris, France
[21] Inst Canc Paris CARPEM, F-75006 Paris, France
关键词
epithelial ovarian cancer; FIGO stage IV; metastatic patterns; prognosis; pleural involvement; overall survival; FALLOPIAN-TUBE; CLASSIFICATION; SURVIVAL; DISEASE; IMPACT; RECOMMENDATIONS; CYTOREDUCTION; COMPLICATIONS; METASTASES; PATHOLOGY;
D O I
10.3390/cancers15030706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The identification of prognostic factors is important to improve the management of patients with ovarian cancer (OC). The staging classification of OC was revised in 2014 and 2018 by the FIGO (International Federation of Gynecology and Obstetrics) Gynecological Oncology Committee and dichotomizes stages IV into stage IVA and IVB. The FIGO classification aims to establish a disease severity scale and to group patients with similar prognoses. The objective of our retrospective, multicenter study was to assess the prognostic impact of this dichotomization and of the initial metastatic localization of patients with FIGO stage IV OC. We showed that, among our 307 patients, FIGO stage IVA patients had a worse prognosis than FIGO stage IVB patients. The initial pleural effusion was a factor of poor prognosis in terms of overall survival. We suggest a modification of the current FIGO staging classification. International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (p = 0.02) and 18 versus 25 months (p = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (p = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (p = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer
    Feng, Zheng
    Wen, Hao
    Ju, Xingzhu
    Bi, Rui
    Chen, Xiaojun
    Yang, Wentao
    Wu, Xiaohua
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (02) : 315 - 319
  • [2] FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited
    Ataseven, Beyhan
    Chiva, Luis M.
    Harter, Philipp
    Gonzalez-Martin, Antonio
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2016, 142 (03) : 597 - 607
  • [3] A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer
    Liu, Hong
    Luo, Min
    Peng, Chunrong
    Huang, Jianmei
    Wang, Dengfeng
    Huang, Jianming
    Zhang, Guonan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV
    Ataseven, Beyhan
    Grimm, Christoph
    Harter, Philipp
    Heitz, Florian
    Traut, Alexander
    Prader, Sonia
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 215 - 220
  • [5] A suggested modification to FIGO stage I endometrial cancer
    Aristizabal, Patrick
    Graesslin, Olivier
    Barranger, Emmanuel
    Clavel-Chapelon, Francoise
    Haddad, Bassam
    Luton, Dominique
    Darai, Emile
    Rouzier, Roman
    Koskas, Martin
    GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 192 - 196
  • [6] Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
    de Jong, Diederick
    Thangavelu, Amudha
    Broadhead, Timothy
    Chen, Inga
    Burke, Dermot
    Johnson, Racheal
    Hutson, Richard
    Kaufmann, Angelika
    Lodge, Peter
    Nugent, David
    Quyn, Aaron
    Theophilou, Georgios
    Laios, Alexandros
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [7] The Effect of Histological Subtypes on Outcomes of Stage IV Epithelial Ovarian Cancer
    Zhou, Juan
    Wu, San-Gang
    Wang, Jun
    Sun, Jia-Yuan
    He, Zhen-Yu
    Jin, Xin
    Zhang, Wen-Wen
    FRONTIERS IN ONCOLOGY, 2018, 8 : 1 - 8
  • [8] Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer
    Timmermans, Maite
    Sonke, G. S.
    Van de Vijver, K. K.
    Ottevanger, P. B.
    Nijman, H. W.
    van der Aa, M. A.
    Kruitwagen, R. F. P. M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (02) : 392 - 397
  • [9] A new prognostic model for FIGO stage 1 epithelial ovarian cancer
    Obermair, Andreas
    Fuller, Arlan
    Lopez-Varela, Elisa
    van Gorp, Toon
    Vergote, Ignace
    Eaton, Lynne
    Fowler, Jeff
    Quinn, Michael
    Hammond, Ian
    Marsden, Donald
    Proietto, Anthony
    Carter, Jonathan
    Davy, Margaret
    Tripcony, Lee
    Abu-Rustum, Nadeem
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 607 - 611
  • [10] Cytoreductive surgery for stage IV epithelial ovarian cancer
    Zang, RY
    Zhang, ZY
    Cai, SM
    Li, ZT
    Chen, J
    Tang, MQ
    Liu, Q
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1999, 18 (04) : 449 - 454